- Home
- DAWN vs DNUT Comparison
DAWN vs DNUT Comparison
Compare DAWN & DNUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- DNUT
- Stock Information
- Founded
- DAWN 2018
- DNUT 1937
- Country
- DAWN United States
- DNUT United States
- Employees
- DAWN N/A
- DNUT N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- DNUT Food Chains
- Sector
- DAWN Health Care
- DNUT Consumer Staples
- Exchange
- DAWN Nasdaq
- DNUT Nasdaq
- Market Cap
- DAWN 624.8M
- DNUT 578.7M
- IPO Year
- DAWN 2021
- DNUT 2021
- Fundamental
- Price
- DAWN $7.15
- DNUT $3.13
- Analyst Decision
- DAWN Strong Buy
- DNUT Buy
- Analyst Count
- DAWN 7
- DNUT 6
- Target Price
- DAWN $27.86
- DNUT $6.22
- AVG Volume (30 Days)
- DAWN 1.1M
- DNUT 3.6M
- Earning Date
- DAWN 10-29-2025
- DNUT 11-06-2025
- Dividend Yield
- DAWN N/A
- DNUT 3.32%
- EPS Growth
- DAWN N/A
- DNUT N/A
- EPS
- DAWN N/A
- DNUT N/A
- Revenue
- DAWN $187,638,000.00
- DNUT $1,538,841,000.00
- Revenue This Year
- DAWN $12.56
- DNUT N/A
- Revenue Next Year
- DAWN $48.02
- DNUT $2.93
- P/E Ratio
- DAWN N/A
- DNUT N/A
- Revenue Growth
- DAWN 2190.50
- DNUT N/A
- 52 Week Low
- DAWN $5.64
- DNUT $2.50
- 52 Week High
- DAWN $16.76
- DNUT $12.68
- Technical
- Relative Strength Index (RSI)
- DAWN 51.15
- DNUT 41.19
- Support Level
- DAWN $7.03
- DNUT $2.95
- Resistance Level
- DAWN $7.58
- DNUT $3.24
- Average True Range (ATR)
- DAWN 0.27
- DNUT 0.18
- MACD
- DAWN -0.04
- DNUT -0.04
- Stochastic Oscillator
- DAWN 29.55
- DNUT 20.65
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About DNUT Krispy Kreme Inc.
Krispy Kreme Inc is a sweet treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-your-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations across the globe. It derives maximum revenue from the U.S. segment.